Navigation Links
Timing, Type of HRT May Determine Breast Cancer Risk
Date:9/16/2009

Starting estrogen-progestagen therapy early may up odds of disease, study shows,,

WEDNESDAY, Sept. 16 (HealthDay News) -- The timing and type of hormone replacement therapy women take to relieve menopausal symptoms seem to determine the degree of breast cancer risk they face, a new French study suggests.

Overall, starting estrogen-progestagen therapy soon after menopause appears to boost the risk of breast cancer, even when only used for short periods of time, according to the study, which was published in the Sept. 14 online issue of the Journal of Clinical Oncology.

Women who began the therapy in the three years after menopause and took it for two years or less had a 54 percent higher risk of breast cancer compared to those who never used the therapy, said study co-author Francoise Clavel-Chapelon, a researcher at the Institut Gustave Roussy in Villejuif, France.

However, they found an exception.

"This 54 percent increase in risk is an average, but does not seem to apply to estrogen-progesterone menopausal hormone therapy, for which no increased risk was observed when used two years or less, even close to menopause," she said. But she noted the risk may still be present, and it was simply not found in the study due to such factors as lack of statistical power.

Many types of progestagens were taken by the women in the study; the finding that progesterone may be safer needs to be confirmed, she stressed.

The new study adds to a growing body of research that is sorting out the risks and benefits of hormone replacement therapy. Until the end of the 1990s, the therapy was viewed as largely beneficial, the authors noted. But with the release of the Women's Health Initiative trial in 2002, research began to show the therapy boosted the risk for blood clots and breast cancer, and did not protect against heart disease, as originally believed.

Later on, some researchers hypothesized that the timing of therapy might affect patients' heart disease risk. The French researchers decided to see if timing might affect breast cancer risk.

They turned to a large French study in which 1,726 invasive breast cancers were diagnosed among 53,310 postmenopausal women from 1992 through 2005.

They took into account hormone use, types of hormones, when the therapy was started and how long it was taken, along with comparing users and non-users.

In addition to finding a 54 percent increased risk for those who took hormone therapy for two years or less within three years of the start of menopause, they also found that short-term treatment of two years or less that was started more than three years after the beginning of menopause didn't increase breast cancer risk. However, longer duration of use elevated risk, no matter when the therapy was begun.

The new study should serve as a warning, said Leslie Bernstein, director of the division of cancer etiology at the City of Hope National Medical Center in Duarte, Calif., who wrote an accompanying editorial.

"The missing piece is, 'How safe is it to take right after menopause in terms of breast cancer risk?'" Bernstein said.

The French study provides some answers, but more research is needed, she said. The regimens typically taken in France are different than those taken by most U.S. women, Bernstein noted. And French women often use skin patches, not oral pills.

Any woman who is taking hormone replacement therapy should check with her doctor to see what hormone formulation is involved if she wants to more accurately assess her breast cancer risk.

While noting that the 54 percent elevated risk found by the French researchers is "worrisome," Bernstein pointed to another study finding -- that once a woman stops hormone therapy, her risk over time declines to that of the general population.

"I see this paper as a warning," Bernstein said. "You want to take a conservative approach."

More information

To learn more about hormone therapy, visit the U.S. National Library of Medicine.



SOURCES: Leslie Bernstein, Ph.D., professor and director, Division of Cancer Etiology, Department of Population Science, City of Hope National Medical Center, Duarte, Calif.; Francoise Clavel-Chapelon, Ph.D., researcher, Institut Gustave Roussy, Villejuif, France; Sept. 14, 2009, Journal of Clinical Oncology, online


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. U.S. Food and Drug Administration Clears Vermillions OVA1(TM) Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass
2. Two Genes May Determine How Well MS Patients Do
3. Utilizing GPS-like Measurement Precision To More Accurately Determine Overall Performance
4. Mylan Reports That the FDA Determined That All Accusations Were Unfounded
5. Study Suggests Preseason Shoulder Strength May Determine Injury Severity for Baseball Pitchers
6. Social class, gender and ethnic group determine adolescents sexual-affective education
7. Snoring Isn't Sexy, LLC Launches Survey to Determine Extent of Drowsy Drivers on Land, Sea and In The Air
8. New American College of Surgeons risk calculator determines colorectal surgery risk
9. CEL-SCI Expands Testing of Its Vaccine to Determine Efficacy Against More Virulent Strain of H1N1 Swine and Other Influenza Viruses
10. Health Plans and IROs Can Work Together to Determine Proper Care for Eating Disorders
11. Oxygen + MRI might help determine cancer therapy success, researchers find
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Timing, Type of HRT May Determine Breast Cancer Risk
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its first-ever ... Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding work ... Practice and Pediatric Emergency Medicine Practice. , “With this award, we recognize ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm ... sciences executive with extensive sequencing and genomics experience, as Vice President of North American ... Hill will be responsible for leading the sales team in the commercialization of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, ... (iPS) cells and other difficult to transfect cells, announces its launch of the ... G9™ Gene Editing System is a complete system for culturing and transfecting ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
Breaking Medicine Technology: